- Home
- ACTG vs AVTX Comparison
ACTG vs AVTX Comparison
Compare ACTG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACTG | AVTX |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 328.4M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACTG | AVTX |
|---|---|---|
| Price | $4.67 | $13.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.00 | ★ $40.57 |
| AVG Volume (30 Days) | 199.1K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $12,004,000.00 | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $3.12 | $4.46 |
| 52 Week High | $5.27 | $24.27 |
Technical Indicators
Market Signals| Indicator | ACTG | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 37.21 |
| Support Level | $4.51 | $13.22 |
| Resistance Level | $4.78 | $15.63 |
| Average True Range (ATR) | 0.12 | 0.94 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 31.91 | 20.04 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.